Search clinical trials for: SPD503 (2 mg)

Total 24814 results

Shire

Completed

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Efficacy and Safety of SPD503 in Combination With Psychostimulants

ADHD

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Maastricht University Medical Center
Shire

Completed

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)

Attention Deficit Disorder

Netherlands
Shire

Completed

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Czechia, Germany, Latvia, Poland, Romania
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Shire

Completed

AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184

Healthy

United States
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Food Effect Study of SPH5030 Tablets.

Advanced Solid Tumor

China
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Shire

Completed

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Shire

Completed

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Proteimax Biotechnology Israel LTD

Recruiting

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Shire

Completed

Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers

Healthy Volunteers

United States
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-positive Advanced Solid Tumors

China
Aaron R. Mangold

Completed

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Cutaneous Lichen Planus

United States
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Novartis Pharmaceuticals

Completed

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Breast Cancer | Hematologic Neoplasms

Netherlands, Switzerland, United Kingdom, United States
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Shire

Completed

The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

Healthy

United States
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
R-Pharm

Terminated

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer (IXTEND)

Breast Neoplasms

United States
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Shire

Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

ADHD

United States
Shire

Completed

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
M's Science Corporation

Completed

Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke

Ischemic Stroke

United Kingdom
M's Science Corporation

Completed

SA4503 8-Week Study in Major Depressive Disorder (MDD)

Depressive Disorder, Major

Finland
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Shire

Completed

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Hivih
Venn Life Sciences

Completed

Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.

Healthy

United Kingdom
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Eisai Inc.

Completed

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Shire

Completed

Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function

Impaired Renal Function

United States
Gannex Pharma Co., Ltd.

Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Nonalcoholic Steatohepatitis (NASH)
NYU Langone Health

Active, not recruiting

Nivolumab Combined With BMS-986253 in HCC Patients

Hepatocellular Carcinoma

United States
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
KLS Martin
Clinical Study Centers, LLC

Recruiting

Prospective Post-market Clinical Follow-up Study of the HBS 2 Resorb Mg in Patients With Intra- and Extraarticular Fractures, Pseudarthroses and Arthrodesis of Small Bones and Bone Fragments.

Arthrosis | Pseudarthrosis | Intraarticular Fracture | Extraarticular Fracture

Germany
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease

3

Subscribe